AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01208064 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Study NCT04621409 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver-enriched antimicrobial peptide 2
Description: IV infusion of LEAP2, approximately 5 hours
Study NCT04621409 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of saline, approximately 5 hours
Study NCT04357275 — intervention group
Intervention type: OTHER
Intervention: ICU treatment
Description: ICU treatment according to standard of care
Study NCT01827007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Volume expansion with gelofusine
Study NCT01911975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
Study NCT01911975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
Study NCT02568384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Onyx BG Meter / App System
Description: Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
Study NCT01929109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study NCT01679821 — intervention group
Intervention type: OTHER
Intervention: A questionnaire and a clinical examination
Description: Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
Study NCT01570465 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
Study NCT01891292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 0.25-0.35 mg/kg/day
Study NCT01891292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine 0.5 mmol/kg
Study NCT01790165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDT067 and Lamisil
Description: Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
Study NCT01310049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days
Study NCT01310049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 32731
Description: * Part 1 and 2: Oral single dose of oral solution or capsule~* Part 3: Twice daily dose of oral solution or capsule for 7 days
Study NCT01739283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP
Study NCT01739283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1
Study NCT01739283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1841788 / darolutamide (ODM-201)
Description: 600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard ADT (androgen deprivation therapy)
Description: As prescribed by the treating physician.
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard ADT (androgen deprivation therapy)
Description: As prescribed by the treating physician.
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: As prescribed by the treating physician.
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: As prescribed by the treating physician.
Study NCT02799602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone \[LHRH\] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
Study NCT00950872 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Duet TRS
Description: Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
Study NCT00963209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00963209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00963209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02556242 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted indoor residual spraying
Description: IRS is carried out in neighbourhoods of cases
Study NCT02556242 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Generalised Indoor residual spraying
Description: IRS is carried out as normally practiced
Study NCT04643678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Patient will receive Anakinra 100 mg SC injection every 12 hours for 3 days, then 100 mg once daily from day 4 to day 7 plus Standard of Care
Study NCT04643678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Patients will receive the Standard of Care therapy as per the local treatment protocol
Study NCT00914888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.
Study NCT00914888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study NCT00914888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside
Description: Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.
Study NCT00914888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAP: Ceftriaxone, plus if applicable oral clarithromycin
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study NCT02281942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT02281942 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education
Study NCT00257296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and Intervention
Description: Screening for intimate partner violence and providing a multi-faceted intervention which depends on the needs of the patient
Study NCT00257296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Screening for intimate partner violence and provide enhanced usual care which includes providing resource list, educating medical staff and partner violence and instructing physicians to help all patients regardless of assigned arm.
Study NCT01798069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: reflective writing
Description: Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
Study NCT01798069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: reading medical publication workshops
Study NCT02941809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open-Label Placebo (OLP)
Description: We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation.
Study NCT01986582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline
Description: Intranasal application
Study NCT01986582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxymetazoline
Description: Intranasal application
Study NCT01986582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyl-propyl-methyl cellulose powder
Description: Intranasal application
Study NCT01986582 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (lactose powder)
Description: Intranasal application
Study NCT01226056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 in combination with sorafenib
Description: Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.
Study NCT04811768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus augmentation
Description: The surgery was performed under local anaesthesia in both groups, lateral window preparation and window coverage was carried out based on randomization.
Study NCT02090439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Study NCT02795104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention via brochure
Description: Educational Intervention via brochure:~In this arm of the educational intervention the participant receives brochures
Study NCT02795104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention via DVD
Description: Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
Study NCT02795104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention-DVD & Telephone Based Navigation
Description: Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
Study NCT04872322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Participants will receive the nerve block preoperatively using 0.5% ropivacaine
Study NCT04872322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.25% Injectable Solution
Description: Participants will receive the nerve block preoperatively using 0.25% ropivacaine
Study NCT04872322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet Pill
Description: After surgery participants will be given a prescription for Percocet to be taken as needed for pain
Study NCT04872322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco Pill
Description: After surgery participants will be given a prescription for Norco to be taken as needed for pain
Study NCT04872322 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foot/Ankle Surgery
Description: Participant will undergo foot or ankle surgery and receive a popliteal nerve block
Study NCT02740608 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OrganOx metra
Description: Normothermic Machine Liver Perfusion
Study NCT01199757 — intervention group
Intervention type: DRUG
Intervention: Fluticasone furoate
Description: cohort of patients receiving fluticasone furate
Study NCT01199757 — intervention group
Intervention type: DRUG
Intervention: mometasone furoate
Description: cohort receiving mometasone furoate
Study NCT01199757 — intervention group
Intervention type: DRUG
Intervention: fluticasone propionate
Description: cohort of patients on fluticasone propionate
Study NCT04057053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% Ophthalmic Solution
Description: Use of Netarsudil 0.02% ophthalmic solution daily after surgery
Study NCT04057053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Netarsudil 0.02% Ophthalmic Solution
Description: Use of Netarsudil 0.02% ophthalmic solution daily after surgery
Study NCT00922597 — intervention group
Intervention type: BIOLOGICAL
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
Study NCT01937390 — intervention group
Intervention type: DRUG
Intervention: Tiotropium 2x2.5µg tiotropium (equivalent to 2x3.154µg tiotropium bromide monohydrate) Respimat® inhaler and cartridge Solution for inhalation
Description: Respimat® inhaler and cartridge Solution for inhalation
Study NCT01937390 — intervention group
Intervention type: DRUG
Intervention: Indacterol 300 µg
Description: inhalation powder
Study NCT01937390 — intervention group
Intervention type: DRUG
Intervention: Tiotropium 18µg (equivalent to 22.5µg tiotropium bromide monohydrate) HandiHaler® device Inhalation powder, hard capsule
Description: HandiHaler® device Inhalation powder, hard capsule
Study NCT01937390 — intervention group
Intervention type: DRUG
Intervention: Indacterol 150 µg
Description: inhalation powder
Study NCT00221507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder-Recall-Outreach
Study NCT00221507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Study NCT00221507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Navigator
Study NCT02382666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rolapitant
Study NCT02532335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: active drug
Study NCT02532335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid
Description: active drug
Study NCT02532335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Obeticholic acid placebo
Description: matching placebo
Study NCT01698970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)
Description: 1- 6 test products/day
Study NCT01698970 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2- excipients (150 mg) in capsule (control)
Description: 2- 6 control poducts/day
Study NCT05385380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe motherhood Promotion
Description: Interventions included the training of community members, who subsequently led participatory educational sessions on safe motherhood topics with pregnant females. The project staff identified 2 community health workers and 15 female volunteers from each kebele cluster and trained them as research implementers. The implementers received 2 days of training led by the project team. The project staff and research implementers conducted safe-motherhood training comprising 2 h of information presentations and discussions with pregnant females in the intervention clusters. In addition to the pregnant-female intervention strategy, we also conducted a four-day training programme on clinical skills for local maternal and child healthcare providers in the study area. MWH intervention was also implemented in the intervention group, including upgrades to existing MWH services per national guidelines to standardize services and create a homelike environment for pregnant females.
Study NCT01173965 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEA
Description: Microwave endometrial ablation device
Study NCT03418259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KCS Medical Device
Description: Patient treated 6 times with the Active KCS Medical Device during 2 weeks.
Study NCT03418259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KCS Medical Device
Description: Patient treated 6 times with the Inactive KCS Medical Device during 2 weeks.
Study NCT03307928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test Protocol
Description: The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
Study NCT03307928 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography Assessment
Description: The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
Study NCT02511925 — intervention group
Intervention type: OTHER
Intervention: Weekly poster of unit performance
Description: Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
Study NCT02511925 — intervention group
Intervention type: OTHER
Intervention: Daily email of personal feedback
Description: Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
Study NCT02511925 — intervention group
Intervention type: OTHER
Intervention: Active reminder from badge
Description: The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
Study NCT04001803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA+RPV LA
Description: Subjects will receive one tablet of CAB 30 milligram(mg) + RPV 25 mg once daily from Day 1 for 1 month. During month 1, subjects will receive 600 mg of CAB LA injection+ 900 mg of RPV LA injection. Following Month 1, subjects will receive 400mg of CAB LA + 600mg of RPV LA at each subsequent injection.
Study NCT02377609 — intervention group
Intervention type: DRUG
Intervention: Tacrolimus
Description: oral
Study NCT03899857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be added to standard of care